Destruction of DNA-Binding Proteins by Programmable Oligonucleotide PROTAC (O'PROTAC): Effective Targeting of LEF1...

Area of Science:

• Molecular Biology
• Drug Discovery
• Cancer Research

Background:

• DNA-binding proteins, including transcription factors (TFs), are crucial in cellular processes and disease pathogenesis.
• TFs are often considered undruggable due to lack of enzymatic sites or ligand-binding pockets.
• Proteolysis-targeting chimera (PROTAC) technology facilitates protein degradation via E3 ligase proximity.

Purpose of the Study:

• To develop a novel class of PROTACs, termed O'PROTACs, for targeting DNA-binding proteins.
• To demonstrate the efficacy of O'PROTACs in degrading cancer-related transcription factors.
• To explore O'PROTACs as a therapeutic strategy against diseases like cancer.

Main Methods:

• Engineering bifunctional O'PROTAC molecules incorporating TF-recognizing oligonucleotides.
• Utilizing O'PROTACs to induce ubiquitination and proteasomal degradation of target TFs (LEF1 and ERG).
• Assessing the impact of O'PROTACs on TF transcriptional activity and cancer cell proliferation in vitro and in vivo.

Main Results:

• O'PROTACs successfully degraded lymphoid enhancer-binding factor 1 (LEF1) and ETS-related gene (ERG).
• Degradation of LEF1 and ERG by O'PROTACs inhibited their transcriptional activity.
• O'PROTAC treatment impeded cancer cell growth in vitro and in vivo.

Conclusions:

• O'PROTACs represent a viable strategy for targeting previously undruggable DNA-binding proteins.
• The programmable nature of O'PROTACs allows for broad applicability to various transcription factors.
• O'PROTACs offer a promising therapeutic approach for treating cancers and other diseases driven by DNA-binding proteins.